ONKURE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
ONKURE THERAPEUTICS, INC. (OKUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $50.20 per share for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2024-11-07
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2024-03-31 was $4.90, a 4.30% decline year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2023-03-31 was $5.12, a 21.90% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2022-03-31 was $4.20, a 68.67% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2021-03-31 was $2.49.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $4.91, a 5.58% decline from fiscal 2022.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $5.20, a 35.42% increase from fiscal 2021.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2021 was $3.84.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2024-09-30 | $50.20 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $5.04 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $4.90 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $4.91 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $4.94 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $4.93 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $5.12 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $5.20 10-K · filed 2023-03-27 | |||
| 2022-09-30 | $5.02 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $4.84 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $4.20 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $3.84 10-K · filed 2022-03-23 | |||
| 2021-09-30 | $2.67 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $2.67 10-Q · filed 2021-08-11 | |||
| 2021-03-31 | $2.49 10-Q · filed 2021-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |